Piper Jaffray
Piper Jaffray is a client-focused, middle market investment bank and institutional securities firm founded in 1895 and based in Minneapolis, Minnesota.
Its Investment Banking activities include raising capital through equity and debt financings for corporate clients; providing financial advisory services relating to mergers and acquisitions to consumer, financial institutions, health care, technology, alternative energy, business services, and industrial growth sectors; underwriting debt issuances for government and non-profit clients; and providing financial advisory and interest rate risk management services.
The company's equity and fixed income institutional sales and trading activities include equity and fixed income advisory and trade execution services for public and private corporations, public entities, non-profit clients, and institutional investors.
-
Genzyme (GENZ) Target Edged Higher to $73 at Piper Jaffray
-
Trading Radar for 07/21: Coca-Cola (KO), eBay (EBAY), Baidu.com (BIDU), Qualcomm (QCOM) Report
-
Piper Jaffray Maintains an 'Overweight' Rating on Genzyme (GENZ); Lowering Price Target
-
Notable Analyst Rating Changes 06/01: LVS, GENZ, V, CPT Upgraded; CNK, BEAT, GLW, AEO Downgraded
-
Piper Jaffray Reiterates an 'Overweight' Rating on Genzyme (GENZ); Making the Right Moves
-
Piper Jaffray Upgrades Genzyme (GENZ) to Overweight
-
Trading Radar for 04/21: AT&T (T), eBay (EBAY), Wells Fargo (WFC), Lockheed Martin (LMT), Freeport-McMoRan (FCX) Report
-
Piper Jaffray Initiates Coverage on Genzyme (GENZ) with a Neutral; Turning The Corner
-
Piper Jaffray Maintains an 'Overweight' on ISIS Pharmaceuticals (ISIS); Price Target Cut
-
Piper Jaffray Maintains an 'Overweight' on ISIS Pharmaceuticals (ISIS); Price Target Lowered
-
Trading Radar for 10/21: Boeing (BA), eBay (EBAY), Wells Fargo (WFC), US Bancorp (USB), Eli Lilly (ELY), St. Jude Medical (STJ) Report
-
Notable Analyst Rating Changes 9/18: ETFC, SNDK, TOL, SBUX, PG, AMED Upgraded; SCHW, GENZ, MDC, IMAX, MOT Downgraded
-
Piper Jaffray Downgrades Osiris Therapeutics (OSIR) to Neutral; Disappointing Top-Line Data From Phase III Trials
-
Notable Analyst Rating Changes 3/27: AMGN, COP, JCP, UPS, CAG, CPWR Upgraded; FSLR, PBR, UTIW, STP, BHP Downgraded
-
Piper Jaffray Initiates Coverage on Genzyme (GENZ) with a Buy; Attractive Entry Point
-
Notable Analyst Rating Changes 3/9: KO, AMZN, BBY, GENZ Upgraded; PBR, BBD, AFL Downgraded
-
Notable Analyst Rating Changes 3/6: M, MDR, FDO, LOW Upgraded; GENZ, RIG, GU Downgraded
-
David Moenning's Daily State of the Markets: 3/3
-
Notable Analyst Rating Changes 3/3: DWA, BBD, ARO Upgraded; UBS, CS, DHI, CTX, GENZ Downgraded
-
David Moenning's Daily State of the Markets: 10/22
-
David Moenning's Daily State of the Markets: 7/23
